Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 699

1.

Data processing on a comparative evaluation of the extraction and analysis procedures for urinary phospholipid and lysophospholipid using MALDI-TOF/MS.

Li X, Nakayama K, Goto T, Akamatsu S, Shimizu K, Ogawa O, Inoue T.

Data Brief. 2019 Jul 15;25:104275. doi: 10.1016/j.dib.2019.104275. eCollection 2019 Aug.

2.

Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology.

Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O.

Int J Clin Oncol. 2019 Aug 12. doi: 10.1007/s10147-019-01520-z. [Epub ahead of print] Review.

PMID:
31407168
3.

Efficacy of Immediate Postoperative Instillation of Chemotherapy for Primary Non-Muscle-Invasive Bladder Cancer in Real-World Clinical Practice.

Murakami K, Hamada A, Teramoto Y, Matsumoto K, Kita Y, Saito R, Yamasaki T, Matsui Y, Inoue T, Ogawa O, Kobayashi T.

Clin Genitourin Cancer. 2019 May 30. pii: S1558-7673(19)30178-8. doi: 10.1016/j.clgc.2019.05.028. [Epub ahead of print]

PMID:
31402280
4.

TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer.

Kawahara T, Kojima T, Kandori S, Kurobe M, Yoshino T, Kimura T, Nagumo Y, Ishituka R, Mitsuzuka K, Narita S, Kobayashi T, Matsui Y, Ogawa O, Sugimoto M, Miyazaki J, Nishiyama H.

PLoS One. 2019 Aug 1;14(8):e0220173. doi: 10.1371/journal.pone.0220173. eCollection 2019.

5.

Efficacy and Safety of Carboplatin Plus Paclitaxel as the First-, Second-, and Third-line Chemotherapy in Men With Castration-resistant Prostate Cancer.

Fujiwara M, Akamatsu S, Sumiyoshi T, Segawa T, Mizuno K, Yoshino T, Goto T, Sawada A, Saito R, Kobayashi T, Yamasaki T, Inoue T, Ogawa O.

Clin Genitourin Cancer. 2019 Jun 12. pii: S1558-7673(19)30179-X. doi: 10.1016/j.clgc.2019.04.017. [Epub ahead of print]

PMID:
31307917
6.

Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma.

Goto M, Chamoto K, Higuchi K, Yamashita S, Noda K, Iino T, Miura M, Yamasaki T, Ogawa O, Sonobe M, Date H, Hamanishi J, Mandai M, Tanaka Y, Chikuma S, Hatae R, Muto M, Minamiguchi S, Minato N, Honjo T.

Sci Rep. 2019 Jul 12;9(1):10144. doi: 10.1038/s41598-019-46548-3.

7.

Comparative evaluation of the extraction and analysis of urinary phospholipids and lysophospholipids using MALDI-TOF/MS.

Li X, Nakayama K, Goto T, Akamatsu S, Shimizu K, Ogawa O, Inoue T.

Chem Phys Lipids. 2019 Sep;223:104787. doi: 10.1016/j.chemphyslip.2019.104787. Epub 2019 Jun 27.

PMID:
31255592
8.

Impact of Previous, Simultaneous or Subsequent Bladder Cancer on Prognosis after Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.

Kuroiwa K, Inokuchi J, Nishiyama H, Kojima T, Kakehi Y, Sugimoto M, Tanigawa T, Fujimoto H, Gotoh M, Masumori N, Ogawa O, Eto M, Ohyama C, Yokomizo A, Matsuyama H, Ichikawa T, Mizusawa J, Eba J, Naito S; Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG).

J Urol. 2019 Jun 28:101097JU0000000000000422. doi: 10.1097/JU.0000000000000422. [Epub ahead of print]

PMID:
31251717
9.

[A Case of Late Onset Nivolumab-Induced Interstitial Nephritis in a Patient with Metastatic Renal Cell Carcinoma].

Hattahara K, Yamasaki T, Sawada A, Tanigaki K, Endo S, Teramoto Y, Banno H, Fuchigami Y, Suzuki R, Fujiwara M, Hida T, Yoshino T, Kita Y, Goto T, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O.

Hinyokika Kiyo. 2019 May;65(5):157-161. doi: 10.14989/ActaUrolJap_65_5_157. Japanese.

PMID:
31247693
10.

Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer.

Akamatsu S, Kubota M, Uozumi R, Narita S, Takahashi M, Mitsuzuka K, Hatakeyama S, Sakurai T, Kawamura S, Ishidoya S, Hoshi S, Ishida M, Mizuno K, Ogura K, Goto T, Terada N, Kobayashi T, Yamasaki T, Inoue T, Tsuchiya N, Ohyama C, Arai Y, Habuchi T, Morita S, Ogawa O.

Eur Urol Oncol. 2019 May;2(3):320-328. doi: 10.1016/j.euo.2018.10.011. Epub 2018 Nov 23.

PMID:
31200847
11.

Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation.

Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, Akamatsu S, Ogawa O, Mizowaki T.

Int J Clin Oncol. 2019 May 31. doi: 10.1007/s10147-019-01478-y. [Epub ahead of print]

PMID:
31152322
12.

Low bladder capacity is an important predictor for comorbidity of interstitial cystitis with Hunner's lesion in patients with refractory chronic prostatitis/chronic pelvic pain syndrome.

Ueda M, Sengiku A, Kono J, Negoro H, Saito R, Yoshimura N, Ogawa O, Ueda T.

Int J Urol. 2019 Jun;26 Suppl 1:53-56. doi: 10.1111/iju.13975.

PMID:
31144759
13.

No Effect of Digoxin on Rosuvastatin Pharmacokinetics in Healthy Subjects: Utility of Oita Combination for Clinical Drug-Drug Interaction Study.

Otani N, Wakuda H, Imai H, Kuranari M, Ishii Y, Ito Y, Okubo A, Ogawa O, Takeda K, Ohyama T, Hasunuma T, Uemura N.

Clin Transl Sci. 2019 May 16. doi: 10.1111/cts.12646. [Epub ahead of print]

PMID:
31095880
14.

Reply by Authors.

Fukunaga A, Kawaguchi T, Funada S, Yoshino T, Tabara Y, Matsuda F, Yoshimura K, Ogawa O, Negoro H; Nagahama Study Group.

J Urol. 2019 Aug;202(2):360-361. doi: 10.1097/01.JU.0000559826.09631.1d. Epub 2019 Jul 8. No abstract available.

PMID:
31095468
15.

Downregulation of RalGTPase-activating protein promotes invasion of prostatic epithelial cells and progression from intraepithelial neoplasia to cancer during prostate carcinogenesis.

Uegaki M, Kita Y, Shirakawa R, Teramoto Y, Kamiyama Y, Saito R, Yoshikawa T, Sakamoto H, Goto T, Akamatsu S, Yamasaki T, Inoue T, Suzuki A, Horiuchi H, Ogawa O, Kobayashi T.

Carcinogenesis. 2019 May 6. pii: bgz082. doi: 10.1093/carcin/bgz082. [Epub ahead of print]

PMID:
31058283
16.

Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes.

Tanaka N, Nishimura K, Okajima E, Ina K, Ogawa O, Nagata H, Akakura K, Fujimoto K, Gotoh M, Teramukai S, Hirao Y.

Int J Urol. 2019 Aug;26(8):797-803. doi: 10.1111/iju.14009. Epub 2019 May 5.

PMID:
31055879
17.

Consecutive Prostate Cancer Specimens Revealed Increased Aldo⁻Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer.

Miyazaki Y, Teramoto Y, Shibuya S, Goto T, Okasho K, Mizuno K, Uegaki M, Yoshikawa T, Akamatsu S, Kobayashi T, Ogawa O, Inoue T.

J Clin Med. 2019 May 1;8(5). pii: E601. doi: 10.3390/jcm8050601.

18.

Hormone Therapy and Castration Resistance of Prostate Cancer.

Arai Y, Ogawa O.

Can J Urol. 2019 Apr;26(2):9686. No abstract available.

19.

Recurrent Aphthous Stomatitis Caused by Cytomegalovirus, Herpes Simplex Virus, and Candida Species in a Kidney Transplant Recipient: A Case Report.

Ito K, Okuno T, Sawada A, Sakai K, Kato Y, Muro K, Yanagita M, Teramoto Y, Yamasaki T, Inoue T, Ogawa O, Kobayashi T.

Transplant Proc. 2019 Apr;51(3):993-997. doi: 10.1016/j.transproceed.2019.01.058. Epub 2019 Jan 26.

PMID:
30979493
20.

Estimating the Net Utility Gains Among Donors and Recipients of Adult Living Donor Kidney Transplant.

Hiragi S, Goto R, Tanaka Y, Matsuyama Y, Sawada A, SakaI K, Miyata H, Tamura H, Yanagita M, Kuroda T, Ogawa O, Kobayashi T.

Transplant Proc. 2019 Apr;51(3):676-683. doi: 10.1016/j.transproceed.2019.01.049. Epub 2019 Jan 26.

PMID:
30979450
21.

Laparoscopic radical cystectomy in octogenarians: analysis of a Japanese multicenter cohort.

Ito K, Kanno T, Sawada A, Saito R, Kobayashi T, Yamada H, Inoue T, Ogawa O.

Int J Clin Oncol. 2019 Sep;24(9):1081-1088. doi: 10.1007/s10147-019-01446-6. Epub 2019 Apr 10.

PMID:
30972505
22.

RBM10-TFE3 renal cell carcinoma characterised by paracentric inversion with consistent closely split signals in break-apart fluorescence in-situ hybridisation: study of 10 cases and a literature review.

Kato I, Furuya M, Baba M, Kameda Y, Yasuda M, Nishimoto K, Oyama M, Yamasaki T, Ogawa O, Niino H, Nakaigawa N, Yano Y, Sakamoto K, Urata Y, Mikami K, Yamasaki S, Tanaka R, Takagi T, Kondo T, Nagashima Y.

Histopathology. 2019 Aug;75(2):254-265. doi: 10.1111/his.13866. Epub 2019 Jun 25.

PMID:
30908700
23.

Sleep Disturbance Worsens Lower Urinary Tract Symptoms: The Nagahama Study.

Fukunaga A, Kawaguchi T, Funada S, Yoshino T, Tabara Y, Matsuda F, Yoshimura K, Ogawa O, Negoro H; Nagahama Study Group.

J Urol. 2019 Aug;202(2):354. doi: 10.1097/JU.0000000000000212. Epub 2019 Jul 8.

PMID:
30865558
24.

Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.

Sumiyoshi T, Mizuno K, Yamasaki T, Miyazaki Y, Makino Y, Okasho K, Li X, Utsunomiya N, Goto T, Kobayashi T, Terada N, Inoue T, Kamba T, Fujimoto A, Ogawa O, Akamatsu S.

Sci Rep. 2019 Mar 11;9(1):4030. doi: 10.1038/s41598-019-40719-y.

25.

[A Case of Advanced Right Renal Pelvic Cancer with Left Supraclavicular Lymph Node Metastasis that Attained Long-Term Survival by Multidisciplinary Treatments].

Imai K, Inoue T, Saito R, Goto T, Sawada A, Akamatsu S, Negoro H, Kobayashi T, Terada N, Yamasaki T, Okubo K, Yoshimura K, Kanematsu A, Ogawa O.

Hinyokika Kiyo. 2019 Jan;65(1):13-17. doi: 10.14989/ActaUrolJap_65_1_13. Japanese.

PMID:
30831672
26.

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone.

Shiota M, Narita S, Akamatsu S, Fujimoto N, Sumiyoshi T, Fujiwara M, Uchiumi T, Habuchi T, Ogawa O, Eto M.

JAMA Netw Open. 2019 Feb 1;2(2):e190115. doi: 10.1001/jamanetworkopen.2019.0115.

27.

Impact of tumor size on patient survival after radical nephrectomy for pathological T3a renal cell carcinoma.

Sugiyama Y, Yatsuda J, Murakami Y, Ito N, Yamasaki T, Mikami Y, Ogawa O, Kamba T.

Jpn J Clin Oncol. 2019 May 1;49(5):465-472. doi: 10.1093/jjco/hyy200.

PMID:
30793163
28.

The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients.

Terada N, Kamoto T, Tsukino H, Mukai S, Akamatsu S, Inoue T, Ogawa O, Narita S, Habuchi T, Yamashita S, Mitsuzuka K, Arai Y, Kandori S, Kojima T, Nishiyama H, Kawamura Y, Shimizu Y, Terachi T, Sugi M, Kinoshita H, Matsuda T, Yamada Y, Yamamoto S, Hirama H, Sugimoto M, Kakehi Y, Sakurai T, Tsuchiya N.

BMC Cancer. 2019 Feb 15;19(1):156. doi: 10.1186/s12885-019-5342-9.

29.

Complications and reoperations after laparoscopic radical cystectomy in a Japanese multicenter cohort.

Kanno T, Ito K, Sawada A, Saito R, Kobayashi T, Yamada H, Inoue T, Ogawa O.

Int J Urol. 2019 Apr;26(4):493-498. doi: 10.1111/iju.13917. Epub 2019 Feb 1.

PMID:
30710377
30.

Initial evaluation of PET/CT with 18 F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients.

Saga T, Nakamoto Y, Ishimori T, Inoue T, Shimizu Y, Kimura H, Akamatsu S, Goto T, Watanabe H, Kitaguchi K, Watanabe M, Ono M, Saji H, Ogawa O, Togashi K.

Cancer Sci. 2019 Feb;110(2):742-750. doi: 10.1111/cas.13911. Epub 2019 Jan 4.

31.

[Initial Clinical Experience of Nivolumab for Metastatic Renal Cell Carcinoma].

Fukunaga A, Yamasaki T, Okuno T, Imai K, Ikeuchi R, Hishiki K, Goto T, Sawada A, Negoro H, Akamatsu S, Saito R, Kobayashi T, Inoue T, Ogawa O.

Hinyokika Kiyo. 2018 Oct;64(10):383-389. doi: 10.14989/ActaUrolJap_64_10_383. Japanese.

PMID:
30543735
32.

Sperm cryopreservation: Clinical and fertility outcomes in male oncological patients with germ cell tumors or hematological disorders.

Negoro H, Matsui Y, Nakayama T, Hatayama H, Ogawa O, Ichioka K.

Reprod Med Biol. 2018 Sep 30;17(4):500-503. doi: 10.1002/rmb2.12246. eCollection 2018 Oct.

33.

Laparoscopic excision of an acquired ureteral diverticulum: A case report.

Negoro H, Inoue T, Imai K, Goto T, Sawada A, Akamatsu S, Saito R, Kobayashi T, Yamasaki T, Ogawa O.

Asian J Endosc Surg. 2018 Oct 24. doi: 10.1111/ases.12663. [Epub ahead of print]

PMID:
30358128
34.

Castration-Resistant Prostate Cancer Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents: Opportunities and Challenges.

Kita Y, Goto T, Akamatsu S, Yamasaki T, Inoue T, Ogawa O, Kobayashi T.

Cancers (Basel). 2018 Sep 21;10(10). pii: E345. doi: 10.3390/cancers10100345. Review.

35.

Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism.

Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Umakoshi H, Ichijo T, Katabami T, Wada N, Ogawa Y, Yoshimoto T, Kawashima J, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Miyauchi S, Kamemura K, Fukuoka T, Yamamoto K, Otsuki M, Suzuki T, Naruse M; JPAS Study Group.

J Clin Endocrinol Metab. 2018 Dec 1;103(12):4456-4464. doi: 10.1210/jc.2018-00866.

PMID:
30165444
36.

Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching.

Onozawa M, Akaza H, Hinotsu S, Oya M, Ogawa O, Kitamura T, Suzuki K, Naito S, Namiki M, Nishimura K, Hirao Y, Tsukamoto T.

Cancer Med. 2018 Oct;7(10):4893-4902. doi: 10.1002/cam4.1735. Epub 2018 Aug 27.

37.

Gliding Basal Cell Migration of the Urothelium during Wound Healing.

Sano T, Kobayashi T, Ogawa O, Matsuda M.

Am J Pathol. 2018 Nov;188(11):2564-2573. doi: 10.1016/j.ajpath.2018.07.010. Epub 2018 Aug 16.

PMID:
30121259
38.

Intravesical prostatic protrusion is not always the same shape: Evaluation by preoperative cystoscopy and outcome in HoLEP.

Ito K, Takashima Y, Akamatsu S, Terada N, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Negoro H.

Neurourol Urodyn. 2018 Sep;37(7):2160-2166. doi: 10.1002/nau.23428. Epub 2018 Aug 10.

PMID:
30095172
39.

A pilot study of highly hypofractionated intensity-modulated radiation therapy over 3 weeks for localized prostate cancer.

Nakamura K, Ikeda I, Inokuchi H, Takayama K, Inoue T, Kamba T, Ogawa O, Hiraoka M, Mizowaki T.

J Radiat Res. 2018 Sep 1;59(5):656-663. doi: 10.1093/jrr/rry060.

40.

A family case with germline TSC1 and mtDNA mutations developing bilateral eosinophilic chromophobe renal cell carcinomas without other typical phenotype of tuberous sclerosis.

Sakamoto H, Yamasaki T, Sumiyoshi T, Utsunomiya N, Takeda M, Kamba T, Nakamura E, Ogawa O.

J Clin Pathol. 2018 Oct;71(10):936-943. doi: 10.1136/jclinpath-2018-205211. Epub 2018 Jun 30.

PMID:
29960980
41.

Clinical Drug-Drug Interaction Potential of BFE1224, Prodrug of Antifungal Ravuconazole, Using Two Types of Cocktails in Healthy Subjects.

Ishii Y, Ito Y, Matsuki S, Sanpei K, Ogawa O, Takeda K, Schuck EL, Uemura N.

Clin Transl Sci. 2018 Sep;11(5):477-486. doi: 10.1111/cts.12557. Epub 2018 May 16.

42.

Characterization of Helicobacter pylori-Naïve Early Gastric Cancers.

Yamada A, Kaise M, Inoshita N, Toba T, Nomura K, Kuribayashi Y, Yamashita S, Furuhata T, Kikuchi D, Matsui A, Mitani T, Ogawa O, Iizuka T, Hoteya S.

Digestion. 2018;98(2):127-134. doi: 10.1159/000487795. Epub 2018 May 2.

PMID:
29719284
43.

[Two Cases of Metastatic and Recurrent Non-Clear Cell Renal Cell Carcinoma Re-Diagnosed as Renal Mucinous Tubular and Spindle Cell Carcinoma during Long-Term Follow-Up].

Kubota M, Yamasaki T, Teramoto Y, Ito K, Takada H, Magaribuchi T, Sawada A, Akamatsu S, Negoro H, Saito R, Kobayashi T, Terada N, Inoue T, Kamba T, Ogawa O.

Hinyokika Kiyo. 2018 Mar;64(3):111-115. doi: 10.14989/ActaUrolJap_64_3_111. Review. Japanese.

44.

[Clinical Utility of Upper Urinary Tract Reconstruction by Ileal-Ureter Substitution].

Okumura Y, Akamatsu S, Okada Y, Negoro H, Kobayashi T, Terada N, Yamasaki T, Matsui Y, Inoue T, Kamba T, Ogawa O.

Hinyokika Kiyo. 2018 Mar;64(3):87-94. doi: 10.14989/ActaUrolJap_64_3_87. Japanese.

45.

Circadian rhythms of micturition during jet lag.

Ito K, Yasuda M, Maeda Y, Fustin JM, Yamaguchi Y, Kono Y, Negoro H, Kanematsu A, Ogawa O, Doi M, Okamura H.

Biomed Res. 2018;39(2):57-63. doi: 10.2220/biomedres.39.57.

46.

High incidence of BK virus-associated hemorrhagic cystitis in children after second or third allogeneic hematopoietic stem cell transplantation.

Umeda K, Kato I, Kawaguchi K, Tasaka K, Kamitori T, Ogata H, Mikami T, Hiramatsu H, Saito R, Ogawa O, Takahashi T, Adachi S.

Pediatr Transplant. 2018 Jun;22(4):e13183. doi: 10.1111/petr.13183. Epub 2018 Apr 14.

PMID:
29654658
47.

Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer.

Aizawa R, Takayama K, Nakamura K, Inoue T, Kobayashi T, Akamatsu S, Yamasaki T, Ogawa O, Mizowaki T.

Int J Clin Oncol. 2018 Aug;23(4):749-756. doi: 10.1007/s10147-018-1265-8. Epub 2018 Mar 19.

PMID:
29556917
48.

Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer.

Masuda N, Ogawa O, Park M, Liu AY, Goodison S, Dai Y, Kozai L, Furuya H, Lotan Y, Rosser CJ, Kobayashi T.

Oncotarget. 2018 Jan 3;9(6):7101-7111. doi: 10.18632/oncotarget.23872. eCollection 2018 Jan 23.

49.

Erratum to: Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma.

Szarvas T, Nyirády P, Ogawa O, Furuya H, Rosser CJ, Kobayashi T.

Methods Mol Biol. 2018;1655:E1. doi: 10.1007/978-1-4939-7234-0_25. No abstract available.

PMID:
29442339
50.

Glucocorticoid receptor expression in resident and hematopoietic cells in IgG4-related disease.

Iguchi T, Takaori K, Mii A, Sato Y, Suzuki Y, Yoshifuji H, Seno H, Ogawa O, Omori K, Bessho K, Kondo S, Yoshizaki T, Nakashima H, Saito T, Mimori T, Haga H, Kawano M, Yanagita M.

Mod Pathol. 2018 Jun;31(6):890-899. doi: 10.1038/s41379-018-0036-4. Epub 2018 Feb 12.

Supplemental Content

Support Center